agenus

NEWS RELEASE

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

2025-08-26

Webcast details updated from the August 11th release

Webcast on Wednesday, August 27, 2025 at 4:00 p.m. EST

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET which introduces a new virtual format to provide an engaging experience for attendees, along with an updated participation link.

Stakeholder Webcast Participation Details

NEW Audience Webcast Link | **https://riverside.fm/studio/agenus-presentation**
Pre-registration is not required.

The program will cover a strategic and financial overview; Zydus partnership momentum and execution; patient needs fueling interest in colorectal cancer (CRC) studies; recent BOT/BAL clinical updates; and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus a MiNK Therapeutics spotlight (Agenus is a significant stakeholder) and upcoming milestones across the portfolio. The session will conclude with a live Q&A.

Speakers to Include:

Garo H. Armen, PhD

Founder, Chairman, CEO of Agenus

Richard M. Goldberg, MD

Chief Development Officer of Agenus

GI oncology expert with 40+ years in CRC research

Nicholas C. DeVito, MD

Assistant Professor of Medical Oncology at Duke University

Primarily treats patients with CRC and gastroesophageal cancers

Research focused on tumor immune evasion and immunotherapy

Chris O'Callaghan, DVM, MSc, PhD

Senior Investigator at Canadian Cancer Trials Group (CCTG)

Jen Buell, PhD

Chief Executive Officer, MiNK Therapeutics

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit **www.agenusbio.com** or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

About Botensilimab (BOT)

Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. Approximately 1,200 patients have been treated across the botensilimab/balstilimab program in phase 1 and phase 2 clinical trials. For more information about botensilimab trials, visit **www.clinicaltrials.gov**.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations and regulatory plans, and the potential benefits of the combination therapy. Words such as "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," "potential," "game-changing," "curative," and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the "Risk Factors" section of Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on forward-looking statements in this release, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investors

917-362-1370 | **investor@agenusbio.com**

Media

781-674-4422 | **communications@agenusbio.com**

Source: Agenus Inc.